Q2 2025 Performance Highlights - Q2 2025 sales reached £7,986 million, a 6% increase[9] - Core EPS increased by 15% to 465 pence[9] - Core operating profit increased by 12% to £2,631 million[10] - Cash generated from operations year-to-date is £37 billion[10] Specialty Medicines Growth - Specialty Medicines sales increased by 15%[9] - Specialty medicines largest business: 40% sales[14] - HIV sales increased by 12% to £1,880 million[56] - Vaccines sales increased by 22%[71] Financial Outlook and Guidance - Expect to deliver towards the top end of 2025 guidance range[9] - Sales growth is projected at 3-5%[24] - Core OP growth is projected at 6-8%[24] - Expect sales of >£40 billion in 2031[18]

Core Insights - Capricor Therapeutics has appointed Dr. Michael Binks as Chief Medical Officer, effective immediately, to lead the advancement of deramiocel for Duchenne muscular dystrophy (DMD) and future pipeline opportunities [1][2] - Dr. Binks has 25 years of experience in clinical development and has held senior roles at Pfizer and GlaxoSmithKline, contributing to the advancement of several first-in-class therapies [2] - Capricor's lead product candidate, deramiocel, is in late-stage development and has shown potent immunomodulatory and anti-fibrotic actions in preserving cardiac and skeletal muscle function in dystrophiopathies [3] Company Overview - Capricor Therapeutics is focused on developing cell and exosome-based therapeutics for rare diseases, with a commitment to innovative treatments [3] - The company has entered into an agreement with Nippon Shinyaku Co., Ltd. for the exclusive commercialization and distribution of deramiocel for DMD in the United States and Japan, pending regulatory approval [6]